Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure

AI Briefing

• – Alloy Therapeutics raises $40M Series E to scale tech-enabled biotech infrastructure, values company at $1 billion.
• – Company will use funds to further develop AI-driven platforms and integrated services for drug discovery and development.
• – Funding marks significant step in Alloy's evolution from antibody discovery pioneer to full-stack biotech infrastructure company.